Topical rebamipide improves lid wiper epitheliopathy

Abstract

Hirotaka Itakura,1,2 Tomoyuki Kashima,2 Mariko Itakura,1 Hideo Akiyama,2 Shoji Kishi2 1Department of Ophthalmology, Maebashi Red Cross Hospital, 2Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Japan Abstract: Administration of topical rebamipide increases the mucin level of tear film and improves the ocular surface in short break-up time type of dry eye. Lid wiper epitheliopathy (LWE) is a disorder of the marginal conjunctiva of the upper eyelid with dry eye symptoms. LWE may be related to mechanical forces during blinking resulting in inflammation of the ocular surface. Rebamipide also has various anti-inflammatory effects. In this report, we tried treatment with topical rebamipide for two cases of LWE. One case had been treated with sodium hyaluronate ophthalmic solution and diquafosol sodium eye drops by other doctors for several weeks. The other case was not previously treated. In both cases, fluorescein staining of the cornea and lid margin was remarkably improved, ocular symptoms decreased, and tear film break-up times increased with rebamipide eye drops four times daily for 2–3 weeks. Topical rebamipide was effective for corneal and conjunctival disorders in LWE. This drug may provide a novel approach to the treatment of LWE. Keywords: corneal erosion, dry eye, lid wiper, Mucosta®, mucin, rebamipide